Investigators at the University of California San Diego School of Medicine and at Xijing Hospital and Sun Yat-sen Cancer Center in China say that DNA methylation can provide effective markers for at least four major cancers. The biomarkers are able to differentiate malignant tissues from normal tissues and also provide information on prognosis and survival, according to the researchers.
“We report that methylation patterns can predict the prognosis and survival, with good correlation between differential methylation of CpG sites and expression of cancer-associated genes. Their findings demonstrate the utility of methylation biomarkers for the molecular characterization, diagnosis, and prognosis of cancer,” write the scientists in a study (“DNA Methylation Markers for Diagnosis and Prognosis of Common Cancers”) that appears online in Proceedings of the National Academy of Sciences.
“Choosing the proper cancer treatment with the best chance of recovery and survival depends greatly upon accurately diagnosing the specific type or subtype of cancer,” said Kang Zhang, M.D., Ph.D., founding director of the Institute for Genomic Medicine and co-director of biomaterials and tissue engineering at the Institute of Engineering in Medicine, both at UC San Diego School of Medicine.
“If you can do that using a minimally invasive biopsy, it has significant implications for cancer science and medicine. Using DNA methylation markers may be a new and more effective a way forward.”
Dr. Zhang and colleagues studied DNA methylation for differentiating tumor tissue and normal tissue for the four most common cancers (lung, breast, colon, and liver) in three different databases. These included a training cohort of 1619 tumor samples and 173 matched adjacent normal tissue samples; a testing cohort of 791 tumor samples from The Cancer Genome Atlas and 93 matched adjacent normal tissue samples and another independent testing Chinese cohort of 394 tumor samples; and 324 matched adjacent normal tissue samples.
They discovered that DNA methylation analysis could predict cancer versus normal tissue with more than 95% accuracy in the three cohorts, comparable to typical diagnostic methods, according to Dr. Zhang.
In addition, the analysis correctly identified 97% colorectal cancer metastases to the liver and 94% colorectal cancer metastases to the lung.
“Since 10% of cancers present as metastatic lesions or cancers of unknown primary origin, identification of tissue of origin is critical for choosing a correct therapy. This new simple method will be of great value to pinpoint the primary source of the tumor,” said Michael Karin, Ph.D., co-senior author of the study and distinguished professor of pharmacology, also at UC San Diego School of Medicine.
Dr. Zhang believes DNA methylation could improve outcomes by providing more accurate diagnoses, particularly of relatively indolent or aggressive tumors that may require more or less aggressive treatment.
“Although we focused on just four common cancers here, we expect that DNA methylation analysis could be easily expanded to aid diagnoses of a much larger number of cancers,” he pointed out. “A great benefit is that this approach requires only a small amount of tissue to obtain adequate DNA for analysis, potentially allowing the use of less invasive biopsies or biopsies of metastatic lesions where the tumor is of unknown primary cancer type.”
He said more studies have been planned to fully explore the clinical applications and potential of DNA methylation and its role in future personalized cancer care.